Illumina's Large Installed System Base Should Insulate It Somewhat From New Entrants
Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...
Illumina weakness ‘overdone,’ says Wolfe Research
Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...
Roche SBX announcement creates more uncertainty for Illumina, says RBC
RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...
FierceBiotech13h
Illumina maps out entry into spatial transcriptomics
Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...
GlobalData on MSN15h
Illumina teases transcriptome profiling tech ahead of 2026 launch
Set for release in 2026, the ‘first-of-its-kind’ technology aims to give researchers the ability to analyse more cells in a ...
Chinese Rivals Seize on Illumina’s Blacklisting to Woo Clients
Beijing’s surprise move to blacklist Illumina Inc. has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant.
The Edge Singapore20h
Sheng Siong, DFI Retail to see some voucher boost; Venture’s role in life sciences ''Illumina-ted'' by PM Wong
‘Anaemic measure’ or a boost? In his Budget 2025 speech, Wong briefly touched on the ongoing stock market review. The main ...